UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~February~~March 2026

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

46, avenue de la Grande Armée, 75017 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

In February 2026, Sanofi published the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3 which are incorporated herein by reference.

Exhibit Index

Exhibit No.		Description
Exhibit 99.1		Press Release dated February 1624, 2026: ~~Beyfortus~~Sanofi ~~study~~and ~~published~~Regeneron’s Dupixent approved in ~~The~~the ~~Lancet~~US ~~Infectious~~as ~~Diseases~~the ~~shows~~first ~~benefit~~and ~~for~~only ~~infants~~medicine ~~beyond~~for ~~first~~allergic ~~RSV~~fungal ~~season~~rhinosinusitis
Exhibit 99.2		Press Release dated February 1727, 2026: ~~Sanofi~~Acoziborole ~~and~~Winthrop, ~~Teva’s~~developed ~~duvakitug~~by ~~phase~~DNDi 2band ~~maintenance~~Sanofi, ~~data~~receives ~~demonstrated~~CHMP ~~clinically~~positive ~~meaningful~~opinion ~~durable~~as ~~efficacy~~three-tablet, insingle-dose ~~ulcerative~~treatment ~~colitis~~for ~~and~~most ~~Crohn’s~~common ~~disease~~form of sleeping sickness
Exhibit 99.3		Press Release dated February 1727, 2026: ~~Filing~~Sanofi ofand ~~the~~Regeneron’s ~~2025~~Dupixent ~~U.S.~~recommended ~~Form~~for ~~20-F~~EU ~~and~~approval ~~French~~to ~~“Document~~treat ~~d’Enregistrement~~chronic ~~Universel”~~spontaneous ~~containing~~urticaria ~~the~~in ~~Annual~~young ~~Financial~~children ~~Report~~with ongoing symptoms despite treatment

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 23, 2026

Dated: March 3, 2026

/s/ Alexandra Roger

Name: Alexandra Roger

Title: Head of Legal Corporate & Finance

Filing Compare · Sanofi